DR REDDYS LABORATORIES LTD
No SEC Form 4 filings for $RDY in the last 30 days.
Dr. Reddy’s Laboratories said it will terminate its Feb 11, 2022 agreement with Novartis India for distribution and promotion of certain brands in India. The termination is linked to a change in Novartis India’s controlling shareholding, per a SEBI Regulation 30 filing to the NSE. Dr. Reddy’s can commercialize the brands until Sept. 30, 2026.
Dr. Reddy’s Laboratories said it will terminate its distribution and promotion agreement with Novartis India Limited for certain brands in India, effective Sept. 30, 2026. The company cited a change in NIL’s controlling shareholding as the reason. Dr. Reddy’s will continue commercializing the affected brands until the termination date.
Dr Reddy’s Laboratories said it ended its distribution and promotion agreement with Novartis India Ltd for select brands in India after a change in Novartis India’s controlling shareholding. Dr Reddy’s will keep commercialising the covered brands until Sept 30, 2026. The filing cited no financial impact and did not name brands. Dr Reddy’s shares rose 0.09% to ₹1,172 on NSE.
Over the past 7 days, alphai's AI scored 5 news stories mentioning RDY (DR REDDYS LABORATORIES LTD). Coverage has skewed bullish: 2 bullish, 3 neutral, and 0 bearish.
Recent RDY coverage spans regulation, financial news and earnings.
Termination of a distribution and promotion agreement in India is a direct commercial reset for RDY, with revenue and channel implications through Sept 30, 2026.
Termination shifts commercial responsibility for affected brands in India, creating near-term transition risk and potential margin/revenue volatility.
Termination shifts India distribution/promotion arrangements, but the company continues commercialization through a defined end date, limiting immediate revenue disruption.
A first-to-market generic launch can pressure branded Bridion pricing and expand hospital formulary access, supporting RDY’s injectables growth narrative.
Regulatory approval is a direct catalyst for US biosimilar commercialization prospects and near-term sentiment.
alphai scores every news story that mentions RDY with an AI model for sentiment and relevance, and aggregates insider trades from DR REDDYS LABORATORIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Dr. Reddy’s Laboratories said it will terminate its Feb 11, 2022 agreement with Novartis India for distribution and promotion of certain brands in India. The termination is linked to a change in Novartis India’s controlling shareholding, per a SEBI Regulation 30 filing to the NSE. Dr. Reddy’s can commercialize the brands until Sept. 30, 2026.
4 min readDr. Reddy’s Laboratories said it will terminate its distribution and promotion agreement with Novartis India Limited for certain brands in India, effective Sept. 30, 2026. The company cited a change in NIL’s controlling shareholding as the reason. Dr. Reddy’s will continue commercializing the affected brands until the termination date.
2 min readDr Reddy’s Laboratories said it ended its distribution and promotion agreement with Novartis India Ltd for select brands in India after a change in Novartis India’s controlling shareholding. Dr Reddy’s will keep commercialising the covered brands until Sept 30, 2026. The filing cited no financial impact and did not name brands. Dr Reddy’s shares rose 0.09% to ₹1,172 on NSE.
3 min readDr. Reddy’s Laboratories (RDY) said it launched the first U.S. generic sugammadex injection, in 200 mg/2 mL and 500 mg/5 mL single-dose vials. It is used to reverse neuromuscular blockade from rocuronium and vecuronium in adults and children 2+. The branded product Bridion had about $1.6B U.S. sales (12 months ended May 2026, IQVIA).
3 min readDr. Reddy’s Laboratories shares rose 1.37% to Rs. 1163.35 on the BSE after the company said the US FDA approved its rituximab biosimilar for the US market. The product is a biosimilar to Rituxan. Fresenius Kabi has exclusive US commercialization rights under a commercialization agreement.
2 min readDr. Reddy’s Laboratories said the US FDA approved its rituximab biosimilar, a version of Rituxan, produced at its Hyderabad facility. The company said Fresenius Kabi will manage US marketing. Dr. Reddy’s said the product is already available in India, Europe, and more than 25 emerging markets, where rituximab treats non-Hodgkin lymphoma and some autoimmune diseases.
2 min readDr. Reddy’s Laboratories said the U.S. FDA approved its rituximab biosimilar on Aug. 1, 2026 for certain B-cell malignancies and autoimmune conditions. Under a strategic deal, Fresenius Kabi will have exclusive rights to market and distribute the product in the U.S. The company cited a successful FDA pre-license inspection at its Bachupally, Hyderabad facility.
3 min readDr. Reddy’s Laboratories said Thailand’s FDA approved its gonorrhea drug NUZOLVENCE (zoliflodacin), following U.S. authorization by about six months. The company confirmed a Business Standard report and referenced a July 27, 2026 joint press release with GARDP. Dr. Reddy’s added the approval is not a material event requiring separate SEBI disclosure.
2 min readDr Reddy’s Laboratories reported Q1FY27 revenue of ₹8,071 crore, down 5.6% YoY and below an analyst estimate of ₹88.05 billion, citing a ₹240 crore semaglutide API-related provision and weaker North America lenalidomide sales. Adjusted EBITDA margin was 15.4% and net cash surplus ₹3,057 crore. CEO said semaglutide commercial supplies may resume by Nov 2026.
7 min readDr. Reddy’s Laboratories shares fell nearly 7% to a 52-week low of ₹1,101 after weak Q1 FY27 results. According to the company, net profit dropped 69% YoY to ₹435 crore and revenue from operations fell 5.5% to ₹8,070.5 crore, with EBITDA margin at 12.5%. The decline was linked to margin pressure and a Semaglutide API quality provision.
5 min read
